2Rajiv A.Add on angiotensin receptor bLockade with maximized ACE inhibition[J].Kidney In,2001,59:2282.
3Iso K,Tada H,Kuboki K,et al.Long 2 term effect ofepaLrestat,an aLdose reductase inhibitor,on the deveLopment of incip ient diabetic nephropathy in type 2diabetic patients[J].JournaL of Diabetes and Its CompLications,2001,15:241.
4Craven P,Derubertis F.SorbiniL supp resses gLomeruLarp rostagLandin p roduction in the strp tozotocin diabetic rat[J].MetaboLism,1989,38:649.
5PHILL IPSA,STEADMAN R,MORR ISEY K,et al.Exposureof human renaL p roximaL tubuLar ceLLs to gLucose Leads toaccumuLation of type Ⅳ coLLagen and fibronectin bydecreased degradation[J].Kidney Int,1997,52:973.
5Derubertis FR, Craven PA. Activation of protein kinase C in glomerular ceil in diabetes mechanisms and potential links to the pathogenesis of diabetic glomerulopathy[J]. Diabetes, 1994;43;1
6Okada S, Ichiki K, Tanokuchi S, et al. Effect of prostaglandin E1 on the renin-aldosterone system in patients with diabetic nephropathy[J]. J Int Med Res,1993;21:126-32
7Young MJ, Veves A, Smith JV,et al. Restoring lower limb blood flow improves conduction velocity in diabetie patients. Diabetologia, 1995,38 :1051-1054.
8Zoja C, Remuzzi G. Role of platelets in progrogressive glomerular disease. Pediatr Nephrol,1995. 495-502.
9Saeki S,Yamamura K,Matsushita M, et al. Iontophoretic application of prostaglandin E1 for improvement in peripheral microcirculation. Int J Clin Pharmaeol Ther, 1998,36:529.
10Okada S,Iehiki K, Tanokuehi S, et al. Effect of prostaglandin E1 on the renin-aldosterone system in patient with diabetic nephropathy. J Int Med Res, 1993,21 : 126-132.
